Molecular profiling of well-differentiated neuroendocrine tumors: Role of ctDNA

#3104

Introduction: Tumor molecular profiling has proven relevant for the clinical management of cancer. Circulating tumor DNA (ctDNA) may be a useful surrogate of tumor tissue when this is insufficient for analysis.

Aim(s): Aims: Rate of test failure, detection rate of pathological alterations (PAs) and impact on management.

Materials and methods: Patients (pts) with well-differentiated neuroendocrine tumors (WdNETs) underwent ctDNA-based molecular profiling (FoundationLiquid®); non-WdNETs (paraganglioma, goblet cell or poorly differentiated neuroendocrine carcinoma) were used for comparison.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Frizziero M, Barriuso J, Kapacee Z, Mansoor W,

Keywords: ctDNA, well-differentiated, neuroendocrine,